Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemiaStephan Stilgenbauer, John F. Seymour, Sebastian Böttcher et al.|Blood Advances|2024Cited by 13